Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00005-020-00602-5 http://scihub22266oqcxt.onion/10.1007/s00005-020-00602-5 33527308!7850901!33527308     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arch+Immunol+Ther+Exp+(Warsz) 2021 ; 69 (1): 1 Nephropedia Template TP {{tp|p=33527308|t=2021. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?|pdf=|usr=}}{{33527308}} gab.com Text DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End JO: Arch Immunol Ther Exp (Warsz) http://www.kidney.de/pget.php?&tw=1&pmid=33527308 #FOAvip A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail. Twit Text FOAVip DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End ????Arch Immunol Ther Exp (Warsz) http://www.kidney.de/pget.php?&tw=1&pmid=33527308 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33527308 #FOAvip English Wikipedia <ref>{{Cite pmid|33527308}}</ref> DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End? #MMPMID33527308 Krejner-Bienias A; Grzela K; Grzela T Arch Immunol Ther Exp (Warsz) 2021[Feb]; 69 (1): 1 PMID33527308show ga A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |COVID-19/complications/enzymology/metabolism[MESH] |Diabetes Mellitus, Type 2/*complications[MESH] |Dipeptidyl Peptidase 4/*metabolism[MESH] |Dipeptidyl-Peptidase IV Inhibitors/pharmacology/*therapeutic use[MESH] |Humans[MESH]DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?(epmc).pdf DeepDyve Pubget Overpricing